The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.1 per share versus the Zacks C

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the ana

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung ca

Sunshine Biopharma (NASDAQ: SBFM - Get Free Report) and Foghorn Therapeutics (NASDAQ: FHTX - Get Fre

Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being highe

Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contribute

Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clin

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the anal

- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a l

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4

Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new cl

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities i

Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform a

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant ca

Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have been assigned a consensus

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX)

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pion

BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy

Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a

Guggenheim analyst Michael Schmidt initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the ana

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B deg

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the ana

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Marke

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the ana

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Marke

HC Wainwright & Co. analyst Andres Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) wi

FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cel

JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) w

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a cli

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(1.58) per share which beat the ana